These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 34322829)
1. Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma. Takigawa K; Hata N; Michiwaki Y; Hiwatashi A; Yonezawa H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Funakoshi Y; Otsuji R; Sako A; Togao O; Yoshiura T; Yoshimoto K; Mizoguchi M J Neurooncol; 2021 Sep; 154(2):187-196. PubMed ID: 34322829 [TBL] [Abstract][Full Text] [Related]
2. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial. Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639 [TBL] [Abstract][Full Text] [Related]
3. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years. Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669 [TBL] [Abstract][Full Text] [Related]
4. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089 [TBL] [Abstract][Full Text] [Related]
5. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270 [TBL] [Abstract][Full Text] [Related]
6. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475 [TBL] [Abstract][Full Text] [Related]
7. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients. Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780 [TBL] [Abstract][Full Text] [Related]
8. The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma. Yamaguchi S; Ishi Y; Motegi H; Okamoto M; Kobayashi H; Hirata K; Oda Y; Tanaka S; Terasaka S; Houkin K J Neurosurg Sci; 2020 Dec; 64(6):502-508. PubMed ID: 30035459 [TBL] [Abstract][Full Text] [Related]
9. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. Zhu P; Du XL; Lu G; Zhu JJ Oncotarget; 2017 Jul; 8(27):44015-44031. PubMed ID: 28467795 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504 [TBL] [Abstract][Full Text] [Related]
11. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870 [TBL] [Abstract][Full Text] [Related]
12. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710 [TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
14. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461 [TBL] [Abstract][Full Text] [Related]
16. Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study. Deuschl C; Moenninghoff C; Goericke S; Kirchner J; Köppen S; Binse I; Poeppel TD; Quick HH; Forsting M; Umutlu L; Herrmann K; Hense J; Schlamann M Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1285-1295. PubMed ID: 28258444 [TBL] [Abstract][Full Text] [Related]
17. A Systematic Review and Meta-Analysis on the Effectiveness of Radiotherapy and Temozolomide Treatment With or Without Bevacizumab in Patients With Glioblastoma Multiforme. Yang F; Wang L; Zhao W; Wang S; Li J; Sun A; Wang M; Wang Z; Chen Z; Heng X Neurol India; 2024 Jul; 72(4):700-707. PubMed ID: 39216020 [TBL] [Abstract][Full Text] [Related]
18. Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment. Darmon I; Morisse MC; Coutte A; Blonski M; Le Rhun E; Taillandier L; Roufai DB; Desenclos C; Trudel S; Faivre JC; Blanchard N; Chauffert B; Boone M J Cancer; 2017; 8(8):1417-1424. PubMed ID: 28638456 [No Abstract] [Full Text] [Related]
19. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. Shields LB; Kadner R; Vitaz TW; Spalding AC Radiat Oncol; 2013 Apr; 8():101. PubMed ID: 23618500 [TBL] [Abstract][Full Text] [Related]
20. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme. Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]